However, while IL-10 based therapy is attractive, further work will be required in order to perfect the stability and delivery of the peptide to the heart, as trials for its use in diseases such as rheumatoid arthritis and Crohn’s disease have found only modest improvements (Mosser and Zhang, 2008). Here, IL10 is linked to rheumatoid arthritis.